Mannkind SEC Filings

MannKind Corporation filed Amendment No. 1 to a prior current report related to its completed merger with scPharmaceuticals Inc. The update focuses on providing fuller financial information for the acquired business and the combined company.

The amendment adds audited consolidated financial statements of scPharma for the year ended December 31, 2024, unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for MannKind for the six months ended June 30, 2025 and the year ended December 31, 2024. It also lists related exhibits, including the merger agreement, a contingent value rights agreement, a loan agreement amendment, and the auditor’s consent, while leaving all other parts of the original report unchanged.

MannKind Corporation executive reports stock sale under pre-set plan. On 11/14/2025, an officer of MannKind Corp (MNKD), serving as EVP Technical Operations, sold 18,777 shares of common stock in an open-market transaction coded as a sale. The weighted average sale price was $5.03 per share, based on individual trades between $5.00 and $5.07. After this transaction, the executive directly beneficially owned 455,211 shares of MannKind common stock. The filing notes that the sale occurred pursuant to a Rule 10b5-1 trading plan that was established on May 14, 2025, indicating the trades were made according to a pre-arranged schedule.

MannKind (MNKD) filed a Form 4 showing its Chief Medical Officer acquired 318,200 shares of common stock via restricted stock units on 11/11/2025 at a price of $0. Following the grant, the reporting person beneficially owned 318,200 shares, held directly.

The RSUs carry a four-year vesting schedule: no shares vest on the first anniversary of the vesting determination date of September 29, 2025, and one-third vests on each anniversary thereafter until fully vested on the fourth anniversary.

MannKind Corporation is discontinuing its Phase 3 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease after an interim analysis for the first 46 participants who completed the double-blind phase showed no sputum culture conversions, indicating futility.

The data safety monitoring board reviewed the results on November 8, 2025 and agreed with stopping the study; no safety issues were identified. MannKind plans to investigate the outcome and apply learnings to MNKD-102, a dry powder clofazimine formulation progressing from pre-clinical toward Phase 1.

MannKind Corporation reported Q3 2025 results with total revenue of $82,130,000, up from $70,079,000 a year ago. Net income was $7,985,000 (basic and diluted EPS $0.03), driven by higher product sales and royalties.

Revenue mix: product revenue $48,274,000, collaborations and services $26,506,000, and royalties $33,319,000. Operating income reached $18,896,000 as total expenses were $63,234,000. Other expense reflected an impairment of available-for-sale investment of $6,409,000.

On the balance sheet, cash and cash equivalents were $127,392,000 and short‑term investments were $132,643,000. A new term loan of $73,428,000 was outstanding. For the nine months, operating cash flow totaled $26,213,000. Stockholders’ deficit narrowed to $(44,552,000). After quarter end, MannKind completed the acquisition of scPharmaceuticals on October 7, 2025 following a $10,000,000 promissory note issued on August 24, 2025.

MannKind Corporation furnished a current report to announce that it issued a press release addressing results of operations and financial condition. The press release is included as Exhibit 99.1. This administrative update signals that the company has released its latest performance communication, with full details contained in the accompanying press release.

MannKind Corp (MNKD) reported an insider Form 4 for its EVP of Technical Operations. On 10/31/2025, the company withheld 17,071 shares of common stock in a transaction coded F, reflecting shares retained by the issuer to cover taxes upon vesting of previously reported RSUs at a price of $5.59 per share.

Following this tax-withholding event, the reporting person directly beneficially owns 473,988 shares of MannKind common stock.

Initial Form 3 filed for Ajay Ahuja reporting no beneficial ownership in MannKind Corp (MNKD). The filing lists Mr. Ahuja as Chief Medical Officer and a director/officer and notes the date of the triggering event as 09/29/2025. The form explicitly states No securities are beneficially owned and is signed on 10/09/2025. This is a routine Section 16 filing showing the officer currently holds no equity or derivative positions in the company.

MannKind Corporation entered into a merger agreement to acquire scPharmaceuticals, Inc. via a tender offer that began on September 8, 2025. The offer paid $5.35 in cash per scPharma share plus one non‑tradable contingent value right (CVR) per share that can pay up to $1.00 total if regulatory and sales milestones are met.

The CVRs pay up to $0.75 for FDA approval of an injection product by September 30, 2026 (reduced amounts for later approval) and up to additional payments tied to trailing 12‑month worldwide net sales of at least $110.0M (with full payment at $120.0M). Approximately 73.47% of scPharma shares were validly tendered by the offer's expiration, with guaranteed delivery notices for ~10.91% more; the merger closed by completing a short-form merger on October 7, 2025.

The acquisition was funded from available cash and borrowings under an amended credit facility that included an incremental delayed draw term loan commitment of $175.0M, and MannKind also funded debt extinguishment of approximately $82.6M. The amended credit terms include a pricing grid tied to a leverage test and an interest margin step‑up to 5.00% if net leverage reaches 5.00:1.00.